NCT05369286

A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors

A Phase 1 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Combination With Toripalimab in Patients With Advanced Solid Tumors

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Maxinovel Pty., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This include two parts, part 1 is a dose escalation study and part 2 is a dose expansion study.

Detailed description

This study is a study of Max-40279-01 in combination with toripalimab in patients with advanced solid tumors. This study includes two Parts, the Part 1 will assess the safety and efficacy of the preset several dose levels of Max-40279-01 and toripalimab, and recommend a dose level of Max-40279-01 combined toripalimab for stage 2. The part 2 is designed to study the efficacy and safety of max-40279-01 combined toripalimab in advanced solid tumors or certain specific tumors.

Conditions

• Solid Tumor

Interventions

Type	Name	Description
DRUG	"MAX-40279-01" and "Toripalimab"	"MAX-40279-01"combined with "Toripalimab"

Timeline

• Start date: 2022-04-11
• Primary completion: 2023-05-31
• Completion: 2023-08-31
• First posted: 2022-05-11
• Last updated: 2022-05-11

Locations

1 site across 1 country: China